Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled at WCLC 2024

Tomas Kauer - Moderator

Sep 9, 2024 - 01:00

Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled at WCLC 2024

Tags:

Previous Article

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan W...

From Kennedy-Nixon to Harris-Trump: Six decades of debate quips, rips and slips

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

Announcing the final group of top VCs to judge the Startup Battlefield 200 Final at TechCrunch Disrupt 2024

Announcing the final group of top VCs to judge the Star...

Tomas Kauer - Mode... Oct 17, 2024

Tesla Cybertruck pushes past Ford Mach-E to become third best-selling EV in America

Tesla Cybertruck pushes past Ford Mach-E to become thir...

Tomas Kauer - Mode... Oct 24, 2024

Oil prices settle lower as OPEC cuts demand forecast on China concerns

Oil prices settle lower as OPEC cuts demand forecast on...

Tomas Kauer - Mode... Sep 11, 2024